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Abstract
Background: Both female reproductive hormones and childhood sexual abuse (CSA) are implicated in migraine
and in menstrually related mood disorders (MRMD). We examined the association of migraine, including
migraine with aura (MA), and history of MRMD or CSA.
Methods: A total of 174 women (mean age 33.9 – 7.6 years) in this cross-sectional study were evaluated for (1)
current MRMD using prospective daily ratings; (2) history of CSA using structured interview; and (3) MA and
migraine without aura using the International Classification of Headaches Disorders II criteria.
Results: Ninety-six women met MRMD criteria (21 of whom had history of CSA) and 78 women were non-
MRMD controls (16 with CSA histories). Migraine with aura was more prevalent in women with MRMD when
compared to non-MRMD controls (11/88 and 0/86, respectively, p = 0.001). In MRMD women only, a CSA
history was associated with higher MA rates (6/21 and 5/67, respectively, p = 0.019). A combination of current
MRMD diagnosis and a history CSA was associated with increased risk for MA, even after adjusting for
potential confounders (odds ratio = 12.08, 95% confidence interval 2.98–48.90, p < 0.001).
Conclusions: Women with MRMD may be vulnerable to the development of MA, and a history of CSA in
women with a MRMD appears to increase that vulnerability. MRMDs and MA should be included among other
poor mental and physical health outcomes of an abuse history. Routine screening for abuse histories would
potentially improve identification of women with increased risk of experiencing abuse-related disorders.
Introduction
Migraine is a disabling condition with a cumulativelifetime incidence reaching 43% among women.1 At-
tacks of migraine with aura (MA) are more prevalent in wo-
men, with a lifetime prevalence rate of approximately 5%, and
are associated with increased risk of ischemic stroke, espe-
cially among women using oral contraceptives.2–5 It is widely
accepted that the sudden withdrawal of estrogen can trigger
some attacks of migraine without aura (MO).6–9 In contrast to
MO, MA is thought to be associated with higher concentra-
tions of estrogen, consistent with the finding that the sup-
pression of endogenous estrogen production reduces the
frequency of auras in migraineurs.8,10,11 Estrogens are also
implicated in cortical spreading depression, an electrophysio-
logical phenomenon of cortical excitation followed by inhi-
bition that is considered to be an underlying biological
mechanism of the aura phase of migraine.12
Psychosocial factors, including traumatic stress during
childhood, were shown to be associated with higher rates of
adult headache and higher than expected rates of mi-
graines.13,14 For example, a recent multicentered study by
Tietjen and colleagues in migraineurs seeking treatment at
headache clinics reported that 58% of their patients had a
history of childhood maltreatment, and that 44% of patients
with childhood sexual abuse (CSA) histories had MA.15 Fur-
thermore, childhood maltreatment was also associated with
elevated concentrations of biomarkers of coagulation, in-
flammation and oxidative stress in migraineurs, suggesting
that adverse childhood experiences can play an important role
in the association of migraine and stroke.16 However, self-
reported questionnaire assessment of abuse histories and lack
of a control group of healthy subjects were limitations of
previous studies.
There is substantial evidence that adverse childhood ex-
periences increase risk for the development of mood disor-
ders.13,14 Our prior research showed that histories of abuse are
significantly more prevalent in women with a menstrually
related mood disorder (MRMD),17,18 and that those histories
predict a unique experimental pain phenotype in women with
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a MRMD.19 Consequently, we sought to examine the associ-
ation of an abuse history and migraine in women with an
MRMD. Menstrual mood disorders are characterized by sig-
nificant emotional and physical symptoms and functional
impairment that is isolated to the luteal phase of the menstrual
cycle.20,21 Additional rationale that women with a MRMD may
be a relevant population in which to examine the link between
an abuse history and migraine is based on the following evi-
dence: (1) MRMD women are differentially sensitive to the
mood destabilizing effects of gonadal steroid hormones;22 (2)
although mood symptoms are a required feature of MRMD,
premenstrual headache is among the diagnostic criteria;20 (3)
headache and other somatic symptoms contribute to luteal
phase functional impairment;20,23 and (4) for both MRMDs24
and MA,25 polymorphisms in the estrogen receptor alpha
(ESR1) may have pathophysiological relevance.
Therefore, for the first time, this report systematically ex-
amines the association of CSA with migraine, including MA,
in women with and without a diagnosis of MRMD, using
standardized criteria for migraine, MRMD, and CSA. We
hypothesized, based on the pathophysiologic role of estrogen
in both MRMD22 and migraine,8 that women with MRMD
would have higher rates of migraines than non-MRMD wo-
men. Based on the evidence that CSA is linked to increased
rates of headaches,15 combined with the evidence that a his-
tory of abuse is associated with different biologic, clinical, and
pain processing sequelae in women with MRMD,17–19 we
hypothesized that in MRMD women, CSA histories would be
related to increased rates of migraines headaches.
Methods
Subjects
During the time period from July 2007 until March 2012 we
carried out a prospective diagnostic study aimed at identify-
ing women suffering from MRMDs as well as non-MRMD
controls in the Chapel Hill, North Carolina area. This diag-
nostic study was intended to serve as a feeder study for other
research studies comparing women with a MRMD diagnosis
to non-MRMD controls for differences in neuroendocrine and
other physiological functions.19,26 Women were recruited via
newspaper, radio or posted advertisements targeting women
with severe premenstrual symptoms (MRMD women) or
without premenstrual symptoms (non-MRMD women). Ad-
vertisements specifically targeting non-MRMD women with
abuse histories were necessary to ensure roughly equivalent
percentages of CSA in the two diagnostic groups.
During an enrollment visit all women were evaluated for
medical history, including MA and MO using the International
Classification of Headache Disorders, 2nd edition (ICHD-II) cri-
teria,2 for Diagnostic and Statistical Manual of Mental disorders,
4th edition (DSM-IV) Axis 1 psychiatric disorders using the
Mini-international neuropsychiatric interview (MINI) struc-
tured psychiatric interview,20,27 and for histories of CSA using
a validated structured interview28 (see below for description
of instruments).
Based on interviews, all women were in good health,
without current chronic medical conditions or current DSM-
IV Axis 1 psychiatric disorders. None of the subjects was
taking prescription medication, including oral contraceptives
or psychotropic medications. The enrollment visit was fol-
lowed by the prospective evaluation for two to three men-
strual cycles of (1) MRMD status using the Daily Record of
Severity of Problems (DRSP), which all women completed on
a daily basis29; and (2) diagnosis of MO or MA.2 During a
subsequent study visit, a history of CSA was assessed by a
trained interviewer.28 All interviews were later reviewed and
coded by an investigator ( J.L.) who was blind to MRMD
status.
MRMD diagnosis
MRMD status was established using the well-validated
DRSP that allows for the quantification of the severity of
physical, emotional and behavioral symptoms using a six-
point scale (1, absent; 2, minimal; 3, mild; 4, moderate; 5,
severe; 6, extreme).29 In order to discourage retrospective
reporting, forms were mailed back weekly. To classify par-
ticipants with MRMD, each met the following criteria: (1) at
least a 30% decrease in emotional symptom severity between
the seven luteal phase days preceding menses compared with
follicular phase days 4–10; (2) a rating of emotional symptoms
as moderate, severe or extreme on at least two of the seven
premenstrual days; (3) remission of symptoms shortly after
the onset of menses followed by a clear symptom-free period
( ‡ 6 consecutive days) during the early-to-mid follicular
phase; and (4) criteria 1–3 met in at least two menstrual
cycles.29,30 Non-MRMD women met the following criteria: (1)
no more than minimal emotional symptoms occurring on
fewer than three days during the premenstrual week; (2) less
than a 30% decrease in emotional symptom severity from the
luteal to the follicular phase; and (3) these criteria met in at
least two menstrual cycles.
In all, 316 women presented as MRMD and 86 as non-
MRMD. However, based on prospective evaluation with the
DRSP, 96 (31%) women that presented as MRMD met the
MRMD criteria and 78 (91%) women that presented as non-
MRMD met non-MRMD criteria and were studied.
Psychiatric histories
Histories of major depressive disorder, anxiety disorders
(panic disorder, generalized anxiety disorder, social phobia,
and agoraphobia) and alcohol and/or substance abuse and/
or dependence were evaluated using the MINI Psychiatric
interview.27 For analytical purposes, histories of all anxiety
disorders were considered together.
Migraines
During the enrollment visit, women were interviewed for
current and past history of MA and MO. They were also in-
structed to complete headache diaries that assessed headache
duration, location, quality, severity, association with routine
physical activity, as well concomitant symptoms, such as
nausea, vomiting, sensitivity to light and sounds. Women
were also asked about aura symptoms, including visual, sen-
sory and speech symptoms. This allowed for the prospective
diagnosis of MA or MO according to ICHD-II criteria.2
Abuse histories
A history of CSA was verified using a validated structured
interview.28 Sexual abuse included the following experiences:
(a) sexual touching with hands, mouth, or objects; (b) making
the subject touch the perpetrator with hands, mouth, or
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objects; and (c) making the subject have vaginal or anal in-
tercourse. To code for CSA, the subject had to be younger than
13 years of age at the time of the first episode of sexual abuse.
Either force or threat of harm was required to meet criteria for
CSA, unless it was implied by the age differential between
perpetrator and victim. This measure of SA history has been
associated with multiple other measures of poor mental and
physical health status in previous studies.28,31 In addition, this
instrument establishes SA history by using behaviorally spe-
cific questions. This type of methodology has been associated
with more reliable and valid responses and with greater re-
ported rates of abuse when compared with pencil-and-paper
assessments.32 Based on large population-based surveys,
most prevalence estimates of lifetime sexual abuse range be-
tween 15% and 25% in the general female population,32 with
slightly lower rates of CSA. Estimates of sexual abuse are
higher when surveying female patients with pain or psychi-
atric illness.32 Surveys using behaviorally specific questions
like the one employed in the current study give the most ac-
curate estimates since relying on documented cases underre-
ports prevalence.
According to MRMD status and CSA histories, women
were classified into one of four subgroups: (1) MRMD women
with CSA histories (n = 21; 12%); (2) MRMD women without
CSA histories (n = 75; 43%); (3) non-MRMD women with CSA
histories (n = 16; 9%); and (4) non-MRMD women without
CSA histories (n = 62; 36%).
The protocol was approved by the University of North
Carolina at Chapel Hill Committee on the Protection of the
Rights of Human Subjects.
Statistical analyses
All continuous data are presented as means – standard
deviations, all categorical data as number and percent. Con-
tinuous variables were distributed normally according to the
Kolmogorov-Smirnov test.
First, by using one-way analysis of variance (ANOVA) and
Pearson Chi-square tests, we evaluated differences in socio-
demographic status (age, education, and race), psychiatric
histories (depression, anxiety, and alcohol and/or substance
abuse and/or dependence) and distributional differences in
the percent of women meeting migraine criteria between the
four subgroups of women stratified by MRMD status and
CSA histories. Significant omnibus differences were followed
by post hoc analyses using the Fisher exact test. Next, by
performing univariate binary logistic regression analyses we
investigated the risk for any migraine, MO, and MA associ-
ated with a MRMD diagnosis only, with CSA history only,
and with the interaction of a MRMD diagnosis and CSA his-
tory. Significant univariate associations were adjusted for
socio-demographic factors and psychiatric histories that were
different between the four subgroups of women. Data are
presented as odds ratios with 95% confidence intervals.
PASW Statistics 18 package was used for data analysis. A
criterion for statistical significance was chosen as a two-tailed
p value of less than 0.05.
Results
Sociodemographic characteristics and psychiatric histories
of all study patients and stratified by MRMD and CSA status
are presented in Table 1. The mean age of the women was
33.9 – 7.6 years. There were no statistically significant differ-
ences in age ( p = 0.42), education ( p = 0.12), race ( p = 0.90) or
histories of anxiety disorders between the four subgroups of
women stratified by MRMD and CSA status (Table 1). There
were significant differences in rates of depression histories
[Pearson Chi-square (3, 173) = 9.14, p = 0.03] and alcohol and/
or substance abuse and/or dependence [Pearson Chi-square
(3, 173) = 25.70, p < 0.001] between the four subgroups of wo-
men stratified by MRMD and CSA status (Table 1). Post hoc
analyses revealed that depression histories were associated
with CSA histories in non-MRMD women ( p = 0.005), but not
in MRMD women ( p = 0.27). Histories of alcohol and/or
substance abuse and/or dependence were associated with
CSA histories in both diagnostic groups ( p = 0.001 for MRMD
and for non-MRMD women).
Of the entire sample, 37 (21%) women were migraineurs:
26 (15%) had MO and 11 (6%) had MA. All auras were visual
and were not necessarily present during every migraine
attack. More women with MRMD compared to non-MRMD
women were migraineurs (25/88 and 12/86, respectively;
Pearson Chi-square (1, 173) = 5.43, p = 0.02) and met criteria for
MA (11/88 and 0/86; Pearson Chi-square (1, 173) = 11.48,
p = 0.001), but not MO (14/88 and 12/86; Pearson Chi-square
(1, 173) = 0.13, p = 0.72). When examined as a function of CSA,
there was a statistically significant difference in percent of the
Table 1. Sociodemographic and Psychiatric Characteristics of All Study Participants
and Stratified by MRMD and Childhood Sexual Abuse Status
All women MRMD Non-MRMD
N = 174 CSA (n = 21) No CSA (n = 75) CSA (n = 16) No CSA (n = 62)
Age, years 33.9 – 7.6 33.0 – 7.2 33.3 – 7.8 32.9 – 6.3 35.2 – 7.8
Educationa 3.1 – 0.8 2.8 – 0.7 3.0 – 0.8 2.9 – 0.9 3.2 – 0.8
Caucasians, n (%) 110 (63) 14 (67) 49 (65) 10 (63) 37 (60)
Depression historyb 61 (35) 11 (52) 26 (35) 9 (56) 15 (24)
Anxiety history, n (%) 28 (16) 3 (14) 13 (17) 4 (25) 8 (13)
Alcohol and/or substance abuse
and/or dependence history, n (%)c
28 (16) 9 (43) 7 (9) 7 (44) 5 (8)
a1 = less than a high school education; 2 = high school degree; 3 = college degree; and 4 = post-graduate degree.
bNon-MRMD women only: CSA > no-CSA, p < 0.05.
cCSA > no-CSA, p < 0.05.
CSA, childhood sexual abuse; MRMD, menstrually related mood disorders.
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sample with MA between the four subgroups of women
[Pearson Chi-square (3, 173) = 22.83, p < 0.001], because in
MRMD women, more women with CSA had MA compared
to women without CSA histories (6/21 and 5/67, respec-
tively; Fisher exact test, p = 0.019) (see Fig. 1). None of the non-
MRMD women had MA, regardless of CSA history. There
were no differences in rates of any migraines [Pearson Chi-
square (3, 173) = 3.91, p = 0.27) or MO (Pearson Chi-square (3,
173) = 2.24, p = 0.52] as a function of CSA histories (Fig. 1).
In univarite binary logistic regression analyses, current
MRMD was associated with increased risk for any migraine
(odds ratio [OR] = 2.45, 95% confidence interval [CI] 1.14–5.26,
p = 0.02), while the interaction of CSA with MRMD status
(OR = 11.84, 95%CI 3.23–43.45, p < 0.001) was associated with
increased risk for MA (Table 2). After adjusting for histories of
depression and alcohol and/or substance abuse and/or de-
pendence history (see Table 1), current MRMD diagnosis re-
mained an independent predictor of increased risk for any
migraine disorder (OR = 2.24, 95%CI 1.02–4.85, p = 0.04), and
the interaction of CSA history with MRMD diagnosis re-
mained a significant predictor of MA (OR = 12.08, 95%CI
2.98–48.90, p < 0.001).
Discussion
A chief finding of the present study was that in our cohort,
only MRMD women suffered from MA, and only in those
women a greater prevalence of MA was associated with CSA
histories. Specifically, the combination of a current diagnosis
of MRMD and a history of CSA was associated with the
greatest risk for MA, even after adjusting for histories of de-
pression and substance abuse.
A potential pathophysiological mechanism contributing to
the association of MA with MRMD may involve female re-
productive hormones since reproductive hormones are im-
plicated in both MRMD22 and MA.8,11,12 For example, during
pregnancy, when estrogen concentrations are steadily in-
creasing and the cyclic declines are eliminated, there is an
increased risk for first episode MA33 as well as worsening of
MA.34 Also, the use of combined oral contraceptives (OCs) is
associated with worsening of MA.9 In contrast, continuous
treatment with ultra-low dose combined hormonal contra-
ceptives (15lg ethinyl estradiol per 24 hours) decreases the
frequency of aura presumably by decreasing endogenous
estrogen production, thereby leading to sustained low con-
centrations of estrogen.11 Estrogens also increase neuronal
excitability and are implicated in the development and
propagation of cortical spreading depression,12 a putative
pathophysiological mechanism underlying MA. In a similar
vein, substantial divergent evidence supports a role for re-
productive hormones in MRMDs. For example, pharmaco-
logically induced hypogonadism eliminates symptoms in
women with a MRMD, while the add-back of estrogen or
progesterone results in the return of symptoms in MRMD
women but not in controls.22 Additionally, while traditional
OCs involving 21 days of active pills and 7 days of placebo
have not proven to be effective in MRMD,35 more recent re-
search has shown low dose OCs with extended hormone
delivery to be effective in reducing premenstrual symptom
severity,36–38 presumably by decreasing endogenous gonadal
hormone production and cyclicity.
It is well documented that migraine, especially MA, is
highly comorbid with psychiatric disorders, including major
depression.39 The bidirectional nature of the association be-
tween MA and major depression suggests a common neuro-
biology between the two disorders. However, to the best of
our knowledge, this is the first report of the comorbidity be-
tween MA and MRMDs, even after controlling for histories of
depression. This comorbidity may be partially accounted for
by an overlapping genetic predisposition for both disorders,
since the same susceptibility genes are implicated in MRMD
and MA. For example, ESR1 polymorphisms are a significant
FIG. 1. Percent of the sample with any migraine, migraine
without aura and migraine with aura in women stratified by
MRMD status and CSA histories. CSA, childhood sexual
abuse; MRMD, menstrually related mood disorders. *Fisher
exact test, p = 0.019.
Table 2. The Associations of MRMD Diagnosis, Childhood Sexual, Abuse History, and Their Interactions
With Any Migraine, Migraine With Aura, and Migraine Without Aura in Univariate
and Multivariate Regression Analyses
Any migraine Migraine with aura Migraine without aura
OR (95% CI) OR (95% CI) OR (95% CI)
Univariate association
MRMD only 2.45 (1.14–5.26), p = 0.02 N/A 1.17 (0.51–2.69), p = 0.72
CSA history only 1.51 (0.65–3.49), p = 0.33 N/A 0.63 (0.20–1.97), p = 0.43
MRMD and CSA 2.1 (0.76–5.52), p = 0.16 11.84 (3.23–43.45), p < 0.001 0.19 (0.03–1.99), p = 0.19
Multivariate associationa
MRMD only 2.24 (1.02–4.85), p = 0.04 - -
CSA history only - - -
MRMD and CSA - 12.08 (2.98–48.90), p < 0.001 -
aAdjusted for histories of depression and alcohol and/or substance abuse and/or dependence (binary logistic regression: enter).
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risk factor for MA, especially in women,25 and are also im-
plicated in MRMDs.24 Thus, MRMDs and MA might share a
common genetic predisposition with respect to a steroid
hormone receptor, which is pathogenically relevant in both
disorders and might play a role in cortical spreading de-
pression. However, further studies addressing these as-
sumptions are needed.
Our finding that CSA predicted MA, but only in MRMD
women, is consistent with previous work showing that a
history of abuse has different biological sequelae in MRMD
versus non-MRMD women.17,18 For example, we have pre-
viously found that histories of abuse were associated with
greater b-adrenergic receptor responsivity in MRMD women
but not in non-MRMD women with an abuse history.18 The
role of altered b-adrenergic receptor function in migraine is
supported by the substantial evidence that b-adrenergic re-
ceptor blockers are probably the most commonly used drugs
for migraine prophylaxis.40 However, not all migraineurs are
responsive to propranolol41, suggesting a heterogeneity in the
pathophysiological mechanisms contributing to migraines,
and hence, in therapeutic response. An intriguing possibility
that remains to be explored is that a history of MRMD or CSA
may predict efficacy of beta-adrenergic blockade for migraine
prophylaxis.
Another possible mechanism linking CSA histories and
MA involves female reproductive hormones, since women
with childhood trauma have elevated concentrations of folli-
cle stimulating hormone as well as elevated concentrations of
dehydroepiandrosterone, a precursor of female reproductive
hormones, when compared to women without such experi-
ences.42,43 Thus, dysregulation in the female reproductive axis
associated with CSA could consequently contribute to the
development of female reproductive hormone dependent
disorders in vulnerable women, including MRMD and mi-
graine. In addition to any effect that childhood adverse ex-
periences may have on the reproductive axis, childhood
maltreatment has also been shown to correlate with bio-
markers of endothelial dysfunction and inflammation.16
Thus, childhood maltreatment may contribute to deleterious
alterations in endothelial function and inflammatory re-
sponses, thereby contributing to the migraine-associated in-
creased susceptibility for stroke.4,5 Genotype can also
moderate the effect that childhood maltreatment has on long-
term mental health outcomes.42,44 Hence, a possible gene–
environment interaction in the development of MA and
MRMDS, and a possible role of CSA, remains to be examined
in future studies. Nonetheless, the results of this study add to
growing evidence that MA and MRMDs may be considered
additional mental and physical health outcomes associated
with childhood adversity. Routine screening for CSA can
potentially identify women at increased risk to experience
abuse-related disorders, and aid in the management of those
disorders.
While the use of validated diagnostic instruments to de-
termine migraine, MRMD and CSA are significant strengths
of this study, and enhance the reliability of our findings, this
study is not without its limitations. These include a moderate
sample size, rendering our results as preliminary, and the
potential lack of generalizability to the population of women
without MRMD since we over sampled for histories of abuse
in that group. Future research should assess female repro-
ductive hormones and vascular biomarkers in relation to
migraine characteristics and abuse histories in women with
MRMD in order to shed light on potential biological mecha-
nisms mediating the link between CSA and MA.
Conclusions
In summary, these preliminary results suggest that
MRMDs are associated with migraine, particularly MA.
Moreover, a CSA history predicted MA in MRMD women,
even after controlling for potential confounders. These find-
ings indirectly suggest that MA and MRMD might share
common pathophysiology and genetic predispositions, and
that CSA may moderate the link between MRMD and MA. If
confirmed in a larger sample, these results would not only
have implications for individualizing prevention and treat-
ment of migraine, particularly MA, in MRMD patients, but
would also suggest that administration of carefully selected
hormonal therapies or b-adrenergic receptor blockers might
be considered in MRMD women with CSA histories.
Acknowledgment
This study was supported by the National Institute of
Mental Health (grant numbers: R01 MH051246, RO1
MH081837, and UL 1RR025747) and The Foundation of Hope
for the Research and Treatment of Mental Illness.
Author Disclosure Statement
Anne Calhoun, MD, receives research support from
GlaxoSmithKline. She is on the advisory board as a consultant
for Ferring, GlaxoSmithKline, MAP, Nautilus, and Zogenix.
Additionally, AC belongs to the speakers bureau for Glaxo-
SmithKline, MAP, Nautilus, and Zogenix. For the remaining
authors, no financial conflicts exist.
References
1. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB. Cumu-
lative lifetime migraine incidence in women and men. Ce-
phalalgia 2008;28:1170–1178.
2. Headache Classification Subcommittee of the International
Headache Society. The International Classification of
Headache Disorders, 2nd edition. Cephalalgia 2004;24 Suppl
1:9–160.
3. Rasmussen BK, Olesen J. Migraine epidemiology. Cepha-
lalgia 1993;13:216–217.
4. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of
ischaemic stroke in people with migraine: Systematic review
and meta-analysis of observational studies. BMJ 2005;330:63.
5. Kurth T. The association of migraine with ischemic stroke.
Curr Neurol Neurosci Rep 2010;10:133–139.
6. Serva WA, Serva VM, de Fatima Costa Caminha M, et al.
Course of migraine during pregnancy among migraine suf-
ferers before pregnancy. Arq Neuropsiquiatr 2011;69:613–619.
7. Martin VT, Lipton RB. Epidemiology and biology of men-
strual migraine. Headache 2008;48 Suppl 3:S124–130.
8. MacGregor EA. Oestrogen and attacks of migraine with and
without aura. Lancet Neurol 2004;3:354–361.
9. Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Napp
G. Migraine with aura and reproductive life events: A case
control study. Cephalalgia 2000;20:701–707.
10. Nagel-Leiby S, Welch KM, Grunfeld S, D’Andrea G. Ovarian
steroid levels in migraine with and without aura. Cepha-
lalgia 1990;10:147–152.
MIGRAINES, MRMDS, AND HISTORIES OF ABUSE 875
11. Calhoun A. Combined hormonal contraceptives: is it time to
reassess their role in migraine? Headache 2012;52:648–660.
12. Eikermann-Haerter K, Kudo C, Moskowitz MA. Cortical
spreading depression and estrogen. Headache 2007;47 Suppl
2:S79–85.
13. Tietjen GE, Peterlin BL. Childhood abuse and migraine:
epidemiology, sex differences, and potential mechanisms.
Headache 2011;51:869–879.
14. Fuh JL, Wang SJ, Juang KD, Lu SR, Liao YC, Chen SP. Re-
lationship between childhood physical maltreatment and
migraine in adolescents. Headache 2010;50:761–768.
15. Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood mal-
treatment and migraine (part II). Emotional abuse as a risk
factor for headache chronification. Headache 2010;50:32–41.
16. Tietjen GE, Khubchandani J, Herial NA, Shah K. Adverse
childhood experiences are associated with migraine and
vascular biomarkers. Headache 2012;52:920–929.
17. Girdler SS, Leserman J, Bunevicius R, Klatzkin R, Pedersen
CA, Light KC. Persistent alterations in biological profiles in
women with abuse histories: influence of premenstrual
dysphoric disorder. Health Psychol 2007;26:201–213.
18. Girdler SS, Sherwood A, Hinderliter AL, et al. Biological cor-
relates of abuse in women with premenstrual dysphoric dis-
order and healthy controls. Psychosom Med 2003;65:849–856.
19. Fleischman DS, Bunevicius A, Leserman J, Girdler SS.
Menstrually Related mood disorders and a history of abuse:
Moderators of pain sensitivity. Health Psychol 2013. DOI:
10.1037/a0031900
20. American Psychiatric Association. Diagnostic and statistical
manual of mental disorders: DSM-IV-TR, 4th ed. Wa-
shington, DC: American Psychiatric Association, 2000.
21. Cunningham J, Yonkers KA, O’Brien S, Eriksson E. Update
on research and treatment of premenstrual dysphoric dis-
order. Harvard Rev Psychiatry 2009;17:120–137.
22. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubi-
now DR. Differential behavioral effects of gonadal steroids
in women with and in those without premenstrual syn-
drome. New Engl J Med 1998;338:209–216.
23. MacGregor EA. Perimenstrual headaches: Unmet needs.
Curr Pain Headache Rep 2008;12:468–474.
24. Huo L, Straub RE, Roca C, et al. Risk for premenstrual
dysphoric disorder is associated with genetic variation in
ESR1, the estrogen receptor alpha gene. Biol Psychiatry
2007;62:925–933.
25. Joshi G, Pradhan S, Mittal B. Role of the oestrogen receptor
(ESR1 PvuII and ESR1 325 C- > G) and progesterone receptor
(PROGINS) polymorphisms in genetic susceptibility to mi-
graine in a North Indian population. Cephalalgia
2010;30:311–320.
26. Bunevicius A, Leserman J, Girdler SS. Hypothalamic-pitui-
tary-thyroid axis function in women with a menstrually re-
lated mood disorder: association with histories of sexual
abuse. Psychosom Med 2012;74:810–816.
27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-in-
ternational neuropsychiatric interview (M.I.N.I.): The de-
velopment and validation of a structured diagnostic
psychiatric interview for DSM-IV and ICD-10. J Clin Psy-
chiatry 1998;59 Suppl 20:22–33;quiz 34–57.
28. Leserman J, Drossman DA, Li Z, Toomey TC, Nachman G,
Glogau L. Sexual and physical abuse history in gastroen-
terology practice: How types of abuse impact health status.
Psychosom Med 1996;58:4–15.
29. Endicott J, Nee J, Harrison W. Daily record of severity of
problems (DRSP): Reliability and validity. Arch Womens
Ment Health 2006;9:41–49.
30. Rubinow DR, Roy-Byrne P, Hoban MC, Gold PW, Post RM.
Prospective assessment of menstrually related mood disor-
ders. Am J Psychiatry 1984;141:684–686.
31. Girdler SS, Pedersen CA, Straneva PA, et al. Dysregulation
of cardiovascular and neuroendocrine responses to stress in
premenstrual dysphoric disorder. Psychiatry Res 1998;81:
163–178.
32. Leserman J. Sexual abuse history: Prevalence, health effects,
mediators, and psychological treatment. Psychosom Med
2005;67:906–915.
33. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G,
Silvestrini M. Sex-hormone-related events in migrainous
females. A clinical comparative study between migraine
with aura and migraine without aura. Cephalalgia 1995;15:
140–144.
34. Aube M. Migraine in pregnancy. Neurology 1999;53:S26–28.
35. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a un-
ique oral contraceptive in the treatment of premenstrual
dysphoric disorder. J Womens Health Gend Based Med
2001;10:561–569.
36. Freeman EW, Halbreich U, Grubb GS, et al. An overview of
four studies of a continuous oral contraceptive (levo-
norgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual
dysphoric disorder and premenstrual syndrome. Contra-
ception 2012;85:437–445.
37. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contracep-
tives containing drospirenone for premenstrual syndrome.
Cochrane Database Syst Rev 2012;2:CD006586.
38. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA.
Treatment of premenstrual dysphoric disorder with a new
drospirenone-containing oral contraceptive formulation.
Contraception 2005;72:414–421.
39. Frediani F, Villani V. Migraine and depression. Neurol Sci
2007;28 Suppl 2:S161–165.
40. Silberstein SD. Treatment recommendations for migraine.
Nat Clin Pract Neurol 2008;4:482–489.
41. Linde K, Rossnagel K. Propranolol for migraine prophylaxis.
Cochrane Database Syst Rev 2004:CD003225.
42. Alemany S, Arias B, Aguilera M, et al. Childhood abuse, the
BDNF-Val66Met polymorphism and adult psychotic-like
experiences. Br J Psychiatry 2011;199:38–42.
43. Kellner M, Muhtz C, Peter F, Dunker S, Wiedemann K,
Yassouridis A. Increased DHEA and DHEA-S plasma lev-
els in patients with post-traumatic stress disorder and a
history of childhood abuse. J Psychiatric Res 2010;44:215–
219.
44. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in
the cycle of violence in maltreated children. Science 2002;
297:851–854.
Address correspondence to:
Adomas Bunevicius, MD, PhD
Department of Psychiatry
University of North Carolina at Chapel Hill
CB#7175, Medical School Wing D
Chapel Hill, NC 27599
E-mail: a.bunevicius@yahoo.com
876 BUNEVICIUS ET AL.
